东部创伤外科协会多中心试验:严重创伤性脑损伤患者伤前抗血栓药物使用与逆转策略的比较
这项东部创伤外科协会资助的前瞻性多中心观察研究纳入15个创伤中心2793例伤前使用抗血栓药物的患者,比较不同药物对颅脑损伤严重度和院内死亡的影响。结果显示,P2Y12抑制剂±ASA及ASA-华法林者颅脑AIS最高;风险校正后ASA-华法林与更高颅脑AIS相关(OR 2.43,95%CI 1.34-4.42)。在严重TBI(头AIS≥3)患者中,抗血小板药逆转(DDAVP和/或血小板输注)或Xa抑制剂逆转(PCC)均未改善生存。结论提示逆转尝试在严重TBI中未见死亡获益。
要点
- 严重TBI(头AIS≥3)使用抗血小板药者,DDAVP和/或血小板输注逆转 vs 未逆转生存率82.9% vs 90.4%,p=0.30,未改善生存。
- 严重TBI使用Xa抑制剂者,PCC逆转 vs 未逆转生存率84.6% vs 84.6%,p=0.68,未改善生存。
- 风险校正后,抗血小板药逆转死亡OR 0.83(95%CI 0.12-5.9,p=0.85);Xa抑制剂逆转OR 0.76(95%CI 0.12-4.64,p=0.77),均无获益。
- 伤前ASA-华法林联合与更高颅脑AIS独立相关(OR 2.43,95%CI 1.34-4.42),为联合治疗中风险最高者。
- P2Y12抑制剂者平均ISS最高(9.1±8.1);P2Y12±ASA及ASA-华法林者颅脑AIS均值最高(1.2±1.6)。
适用人群与场景
- 伤前使用抗血栓药物的严重创伤性脑损伤患者(头AIS≥3),来自15个创伤中心的前瞻性观察队列。
- 研究纳入伤前使用抗血栓药物(阿司匹林、P2Y12抑制剂、华法林、Xa抑制剂等)的创伤患者;排除标准原文未提及。
诊断标准与关键阈值
- 严重TBI定义为颅脑简明损伤定级(head AIS)≥3。
- 抗血小板治疗包括阿司匹林(ASA)和/或P2Y12抑制剂;Xa抑制剂为另一类抗凝药。
处置流程与药物剂量
- 抗血小板药逆转:使用去氨加压素(DDAVP)和/或血小板输注(原文未给出具体剂量、途径、频次)。
- Xa抑制剂逆转:使用凝血酶原复合物(PCC)(原文未给出具体剂量、途径、频次)。
- 原文未提及逆转的启动阈值、目标值或停药标准。
红旗征与不能漏的情况
- 伤前使用ASA-华法林联合治疗者颅脑损伤严重度最高(风险校正OR 2.43),需高度警惕。
- 严重TBI(头AIS≥3)使用抗血小板药或Xa抑制剂者,逆转尝试未改善生存,不能因逆转而延误其他确定性处理。
研究设计与关键结果
- 研究类型:东部创伤外科协会资助的前瞻性、多中心、观察性研究,15个创伤中心,样本量2793例。
- 人群:伤前使用抗血栓药物的创伤患者;主要终点为颅脑损伤严重度和院内死亡率。
- 药物分布:阿司匹林最多(46.1%);P2Y12抑制剂者平均ISS最高(9.1±8.1);P2Y12±ASA及ASA-华法林者颅脑AIS均值最高(1.2±1.6)。
- 风险校正后ASA-华法林与更高颅脑AIS相关(OR 2.43,95%CI 1.34-4.42),校正变量包括ISS、Charlson合并症指数、初始GCS和初始收缩压。
- 严重TBI(头AIS≥3)抗血小板药逆转 vs 未逆转生存率82.9% vs 90.4%(p=0.30);Xa抑制剂PCC逆转 vs 未逆转84.6% vs 84.6%(p=0.68)。
- 风险校正后逆转未改善死亡:抗血小板药OR 0.83(95%CI 0.12-5.9,p=0.85);Xa抑制剂OR 0.76(95%CI 0.12-4.64,p=0.77)。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察性研究;证据等级:预后性,level II。
- 局限:观察性设计,逆转组与未逆转组非随机,可能存在适应症偏倚;原文未报告各逆转策略的具体剂量和时机。
对床旁实践的改变
- 对严重TBI(头AIS≥3)且伤前使用抗血小板药或Xa抑制剂者,不应常规期待逆转改善生存;逆转决策需权衡其他临床目标。
- 伤前使用ASA-华法林联合者颅脑损伤严重度最高,接诊时应优先评估和处置。
- 原文未提及逆转对非严重TBI或未使用抗血栓药物患者的效果,不适用于这些人群。
指南或共识出处
- Eastern Association for the Surgery of Trauma Multicenter Trial: Comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients(J Trauma Acute Care Surg)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma teams are often faced with patients on antithrombotic (AT) drugs, which is challenging when bleeding occurs. We sought to compare the effects of different AT medications on head injury severity and hypothesized that AT reversal would not improve mortality in severe traumatic brain injury (TBI) patients.
METHODS: An Eastern Association for the Surgery of Trauma-sponsored prospective, multicentered, observational study of 15 trauma centers was performed. Patient demographics, injury burden, comorbidities, AT agents, and reversal attempts were collected. Outcomes of interest were head injury severity and in-hospital mortality.
RESULTS: Analysis was performed on 2,793 patients. The majority of patients were on aspirin (acetylsalicylic acid [ASA], 46.1%). Patients on a platelet chemoreceptor blocker (P2Y12) had the highest mean Injury Severity Score (9.1 ± 8.1). Patients taking P2Y12 inhibitors ± ASA, and ASA-warfarin had the highest head Abbreviated Injury Scale (AIS) mean (1.2 ± 1.6). On risk-adjusted analysis, warfarin-ASA was associated with a higher head AIS (odds ratio [OR], 2.43; 95% confidence interval [CI], 1.34-4.42) after controlling for Injury Severity Score, Charlson Comorbidity Index, initial Glasgow Coma Scale score, and initial systolic blood pressure. Among patients with severe TBI (head AIS score, ≥3) on antiplatelet therapy, reversal with desmopressin (DDAVP) and/or platelet transfusion did not improve survival (82.9% reversal vs. 90.4% none, p = 0.30). In severe TBI patients taking Xa inhibitors who received prothrombin complex concentrate, survival was not improved (84.6% reversal vs. 84.6% none, p = 0.68). With risk adjustment as described previously, mortality was not improved with reversal attempts (antiplatelet agents: OR 0.83; 85% CI, 0.12-5.9 [p = 0.85]; Xa inhibitors: OR, 0.76; 95% CI, 0.12-4.64; p = 0.77).
CONCLUSION: Reversal attempts appear to confer no mortality benefit in severe TBI patients on antiplatelet agents or Xa inhibitors. Combination therapy was associated with severity of head injury among patients taking preinjury AT therapy, with ASA-warfarin possessing the greatest risk.
LEVEL OF EVIDENCE: Prognostic, level II.
参考来源
- Yorkgitis BK, Tatum DM, Taghavi S, et al. Eastern Association for the Surgery of Trauma Multicenter Trial: Comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients. J Trauma Acute Care Surg. 2022. PMID: 34570064. doi:10.1097/TA.0000000000003421
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。